Repeat propofol anesthesia does not exacerbate plaque deposition or synapse loss in APP/PS1 Alzheimer's disease mice by Woodhouse, A et al.
RESEARCH ARTICLE Open Access
Repeat propofol anesthesia does not
exacerbate plaque deposition or synapse
loss in APP/PS1 Alzheimer’s disease mice
Adele Woodhouse1* , Carmen Maria Fernandez-Martos1, Rachel Alice Kathryn Atkinson1, Kelsey Anne Hanson1,
Jessica Marie Collins1, Aidan Ryan O’Mara1, Nico Terblanche2,3,5, Marcus Welby Skinner4,5,
James Clement Vickers1 and Anna Elizabeth King1
Abstract
Background: There is increasing interest in whether anesthetic agents affect the risk or progression of Alzheimer’s
disease (AD). To mitigate many of the methodological issues encountered in human retrospective cohort studies
we have used a transgenic model of AD to investigate the effect of propofol on AD pathology.
Methods: Six month-old amyloid precursor protein/presenilin 1 (APP/PS1) transgenic AD mice and control mice
were exposed to 3 doses of propofol (200 mg/kg) or vehicle, delivered at monthly intervals.
Results: There was no difference in the extent of β-amyloid (Aβ) immunolabeled plaque deposition in APP/PS1
mice in vehicle versus propofol treatment groups. We also detected no difference in plaque-associated synapse loss
in APP/PS1 mice following repeat propofol exposure relative to vehicle. Western blotting indicated that there was
no difference in post-synaptic density protein 95, synaptophysin or glutamic acid decarboxylase 65/67 expression in
control or APP/PS1 mice subjected to repeat propofol treatment relative to vehicle.
Conclusions: These data suggest that repeat propofol anesthesia may not exacerbate plaque deposition or
associated synapse loss in AD. Interestingly, this data also provides some of the first evidence suggesting that
repeat propofol exposure in adult wild-type mice does not result in robust long-term alterations in the levels of key
excitatory and inhibitory synaptic markers.
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Background
Alzheimer’s disease (AD) is the most common form of
dementia and is forecast to become an increasing global
burden with aging of the global populations [1]. AD is
characterized by several pathological ‘hallmarks’ including
β-amyloid (Aβ) plaques, neurofibrillary tangles, plaque-
associated dystrophic neurites and neuropil threads. The
majority of AD cases are sporadic in nature [2] and are
likely caused by a combination of genetic susceptibility
and environmental factors that interact to precipitate
disease onset. Exposure to anesthetics is one such envir-
onmental factor that may contribute to the development
and/or progression of AD. There is increasing interest in
the link between anesthetic exposure, post-operative cog-
nitive dysfunction (POCD) and the onset and progression
of AD [3–15]. Notably, best practice for the use of anes-
thetics in people with mild cognitive impairment (MCI)
and AD is not yet defined [3, 16].
As life expectancy is increasing, there is a rise in the
number of elderly people undergoing anesthesia [10],
however, data regarding the effects of anesthesia on the
onset and progression of AD are contentious. Retro-
spective studies have reported that previous exposure to
anesthesia was significantly correlated with an increased
risk of AD in people over 80 years of age [17] and that
there was an inverse correlation between anesthetic ex-
posure before 50 years of age and the age of onset of AD
[18]. However, other retrospective and meta-analyses
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studies have shown no association between anesthetic
exposure and AD [14, 19, 20]. Moreover, there are sub-
stantial methodological issues to consider when inter-
preting the data from prospective randomized clinical
trials; variations in perioperative/anesthetic procedures,
impact of underlying conditions, lack of long-term fol-
low up, poor controls, inadequate cognitive testing and
surgery-associated inflammation [5, 10, 21].
POCD is a well-documented phenomena that shares
mechanistic links with AD. POCD is common following
general anesthesia in the elderly [7, 22, 23] and pre-
sents as memory loss, delirium, depression and im-
paired higher-level cognitive dysfunction [10]. POCD
usually lasts only a few days, but POCD can persist
for weeks and has been implicated in the develop-
ment or progression of AD due to shared molecular
mechanisms (increased CSF/brain Aβ levels and tau
phosphorylation) [10, 22, 23]. Although the extent of
POCD following particular anesthetic agents and
surgery types varies [24]; aging [25, 26], pre-existing
cognitive impairment [26, 27] and harboring the ε4
apolipoprotein allele [26, 28–30] all appear to play a
role in the overall risk.
Propofol is a general anesthetic that is used for out-
patient procedures (colonoscopy, endoscopy) through to
extensive cardiac, hip and spinal surgeries. As older
people often have several co-morbidities and/or chronic
illness, they are commonly subjected to multiple surgical
interventions. Propofol anesthesia has been reported to
result in an increase [31–33], decrease [34, 35] and no
change [36] in the incidence of POCD and dementia in
humans. Likewise rodent studies have reported that
exposure to propofol resulted in no change/decreased
levels of Aβ [11, 37], and no change in plaque or tau
pathology [38]. While behavioral studies following pro-
pofol anesthesia in rodents have observed no change
[11, 38], decreased [39] or improved [13] cognitive func-
tion. However, when elderly patients were studied propo-
fol use associated with POCD in approximately 50% of
cases, even following minor surgery [40, 41].
Propofol acts as a GABAA receptor agonist and a
voltage-gated sodium channel antagonist [42–44] and it
alters synapses in an age-dependent manner. In postna-
tal day 15 (P15) mice propofol exposure increased den-
dritic spine density in pyramidal neurons in the
hippocampus (involved in memory formation and spatial
navigation), the prefrontal cortex (involved in executive
function, attention and memory) and the somatosensory
cortex (which receives and processes sensory informa-
tion from the body) [45, 46]. In contrast, propofol ex-
posure at P5 reduced dendritic spine density in the
prefrontal cortex and this was shown to be long lasting
(up to P90) [45]. No studies to date have examined the
impact of propofol anesthesia on synaptic structures in
adult or aged subjects, which is particularly relevant due
to the synaptic dysfunction and progressive plaque-
associated synaptic loss that occurs in AD [47–49].
We investigated the impact of repeated propofol ex-
posure on plaque deposition and synapses, in the APP/
PS1 transgenic AD mouse that develop Aβ plaques and
synaptic degeneration with aging. By using an AD mouse
model we are able to mitigate many of the methodo-
logical issues encountered in retrospective cohort studies
including variations in perioperative and anesthetic pro-




All experiments were approved by the Animal Ethics
Committee of the University of Tasmania and performed
according to the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (ethics
number A12324). All experiments used male APPSWE/
PSENdE9 (APP/PS1; [50], APP/PS1xYFPH [51]); Jackson
Laboratory, USA, Strain B6.Cg-Tg(Thy1-YFP+/−) HJrs/J,
Stock No. 003782), YFPH and C57Bl/6 wild-type lit-
termate mice at 6 months of age. APP/PS1 and APP/
PS1xYFPH mice over-express APP harboring familial
AD mutations that result in increased expression of
the APP cleavage product Aβ, and the development
of Aβ plaques and synaptic degeneration with aging
[47, 50, 52]. Amyloid plaques and memory deficits
appear at 6–7 months of age in APP/PS1 mice and
are abundant by 9 months, however, APP/PS1 mice
do not develop the neurofibrillary pathology charac-
teristic of human AD [50]. These mice represent a
dynamic model of Aβ plaque and synaptic pathology
that can be experimentally increased [53, 54] or de-
creased [55]. All animals were housed in standard
conditions (12 h light/dark cycle, 20 °C) with ad libi-
tum access to food and water.
Anesthetic exposure
Six-month-old APP/PS1, APP/PS1xYFPH, YFPH and
wild-type mice were randomly allocated to propofol or
vehicle treatment groups; and administered propofol
(200 mg/kg; Norbrook® Laboratories, Australia PTY Ltd)
diluted in Intralipid® (Fresenius Kabi Ltd., UKm 0338–
0519) or a vehicle control (Intralipid®, Fresenius Kabi
Ltd., UKm 0338–0519) intraperitoneally (IP) three times
at 6 (representing pathology onset time-point), 7 and
8 months of age. All animals were then terminally anes-
thetized and perfused at 9 months of age. The dose of
propofol administered (200 mg/kg) results in the loss of
the righting reflex in > 95% of adult mice [56]. During
anesthetic exposure the mice breathed spontaneously
and were kept warm on a heating pad until they
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recovered and were mobile. Information regarding
anesthetic induction and emergence time (indicating by
the presence of the righting reflex) were collected for
each propofol exposure. Statistical analysis of the average
emergence time was performed; a student’s t-test (2
tailed, type 3; Microsoft Excel) with a p value of 0.05
considered statistically significant. Data generated from
APP/PS1 or wild-type mice were not significantly differ-
ent from that of APP/PS1xYFPH or YFPH mice, respect-
ively; thus these data were pooled and designated APP/
PS1 and control experimental groups.
Immunohistochemistry and analysis
Mice were terminally anesthetized (sodium pentobarbit-
one, 110 mg/kg, IP) and transcardially perfused (4%
paraformaldehyde in 0.01 M phosphate buffered saline
(PBS)). Brains were then cryoprotected (18% and 30%
sucrose) and 40 μm serial coronal sections were cut on a
cryostat (Leica CM 1850). Immunohistochemistry for
Aβ plaques (MOAβ-2 antibody: 1:2000, Novus Biologi-
cals, cat no. NBP2–13075) was performed as previously
described [57]. Propofol and vehicle treated APP/PS1
positive mice (n = 8 and 6) and APP/PS1 negative mice
(n = 8 and 7) were used for plaque analysis. Immunola-
beling for synaptic puncta (synaptophysin antibody: 1:
200, Millipore, cat no. AB9272, NIF Antibody Registry
AB_570874) and staining with thioflavin-S (Sigma-Aldrich,
cat no. T-1892) were performed as previously described
[53, 57]. Propofol and vehicle treated APP/PS1 mice (n = 3
for both) were used for synaptic puncta analysis. Negative
control experiments (omitting primary antibodies) elimi-
nated all immunoreactivity. Primary antibodies were visual-
ized with AlexaFluor goat anti-mouse/rabbit secondary
antibodies (1:500, Molecular Probes).
Images of MOAβ2-labeling were captured on a Leica
DM LB2 microscope (NIS-Elements D Imaging Soft-
ware, Nikon Instruments) as previously described [57].
Images of synaptophysin immunolabeling and thioflavin-
S staining were captured on a Perkin-Elmer Ultraview
VOX spinning disk confocal imaging system (Volocity 6.
3 software, Perkin-Elmer) with the same laser power and
exposure settings, as previously described [53]. All image
collection and subsequent image analysis was performed
by an investigator blinded to treatment group allocation.
Analysis of Aβ plaques and thioflavin-S plaque-associated
synapse loss were conducted with a custom unbiased
image segmentation plugin for ImageJ based on a
random-forests machine learning algorithm to segment
images as plaques and synaptic puncta or background
pixels [58]. The classifier was trained using a random se-
lection of cropped images from the data set that were an-
notated with examples of plaques/synaptic puncta and
background pixels to produce a forest of 50 trees with a
maximum depth of 9 nodes. Each tree considered only a
random bag of 5% of the training pixels, sampled with
replacement. All analysis was conducted blinded to animal
genotype/treatment group. Statistical analysis of the
plaque density, average plaque size, plaque load, the dens-
ity of and percentage area occupied by synaptophysin-
immunoreactive synaptic puncta was performed using the
student’s t-test (2 tailed, type 3; Microsoft Excel) for
analysis, with a p value of 0.05 considered statistically sig-
nificant. The n required to power this study could not be
predicted a priori as no previous study had investigated
repeat propofol exposure in the APP/PS1 mouse
model at 6 months of age with the same dosing re-
gime as the current study, nor had any previous stud-
ies used the custom unbiased image segmentation
plugin for ImageJ (based on a random-forests ma-
chine learning algorithm) to segment images as pla-
ques and synaptic puncta or background pixels [58].
Therefore, for the maximum value of change detect-
able for each of our datasets refer to Additional file 1.
Data are presented as the mean ± SEM. Figures were
prepared in Adobe Photoshop and Adobe Illustrator,
with brightness and contrast being enhanced for clar-
ity consistently across images.
Western blot
Propofol and vehicle treated APP/PS1 (n = 3 and 2) and
wild-type control mice (n = 3 for both) were used for
Western blot analysis. At 9 months of age, mice were
terminally anesthetized (sodium pentobarbitone, 110 mg/
kg IP) and transcardially perfused (0.01 M PBS), the neo-
cortex was then quickly removed and frozen in liquid ni-
trogen. Samples were homogenized in RIPA buffer
(Sigma-Aldrich) containing a proteinase inhibitor cocktail
(Roche) as previously [59]. Denatured proteins samples
(20 μg) were electrophoresed into Bolt® Bis-Tris Plus gels
(Invitrogen), transferred to PVDF membranes (BioRad),
and incubated overnight in primary antibody solution at
4 °C. Primary antibodies used for Western blot were
mouse anti-PSD-95 (1:1000; Abcam cat no. ab2723, NIF
Antibody Registry AB_303248), rabbit anti-synaptophysin
(1:1000; Millipore cat no. AB9272, NIF Antibody Registry
AB_570874), mouse anti-GAD65 (1:1000; Abcam cat no.
ab26113, NIF Antibody Registry AB_448989) and mouse
anti-GAD67 (1:1000; Millipore cat no. MAB5406, NIF
Antibody Registry AB_2278725). PSD-95 is a marker of
the postsynaptic density of excitatory synapses, synapto-
physin is a pre-synaptic marker of excitatory and inhibi-
tory synapses, while GAD65 and GAD67 are markers of
presynaptic inhibitory synapses. Membranes were washed
and incubated with the corresponding anti-rabbit or anti-
mouse horseradish peroxidase (HRP)-conjugated secondary
antibody (1:7000; Dako) for 2 h at room temperature. Im-
munoreactive bands were visualized with enhanced chemi-
luminescence (ECL) solution using Luminata Forte
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Western horseradish peroxidase (HRP) substrate (Merck
Millipore, Billerica, MA, USA). Membranes were then
stripped and re-probed with a mouse anti-GAPDH (1:
1000, Millipore cat no. MAB374, NIF Antibody Registry
AB_2107445), as a loading control. Western blot images
were captured with the same exposure for all experimental
groups for each protein of interest.
Results
No difference in emergence time from propofol
anesthesia in APP/PS1 and control mice
To determine whether there was any difference in the
response to propofol anesthesia the emergence time,
indicated by the return of the righting reflex, was
assessed for propofol treated control and APP/PS1
mice. There was no significant difference in the aver-
age emergence time from propofol anesthesia between
APP/PS1 (43.1 ± 8.9 min, n = 9) and control (64.0 ± 17.
6 min, n = 7) mice (p > 0.05).
Repeat propofol exposure did not alter plaque deposition
in the cortex of APP/PS1 mice
We assessed the impact of repeat propofol anesthesia on
Aβ plaque deposition in propofol and vehicle treated
APP/PS1 mice. There was no significant difference in
the Aβ plaque (MOAβ-2-labeled) load between vehicle
(3.80 ± 0.8%) and propofol (3.85 ± 1.0%) treated APP/PS1
mice compared to control mice (p > 0.05, Fig. 1, Table 1).
There was also no significant difference in the average
size or density of Aβ plaques between vehicle (41.6 ± 6.
5 μm2, 0.030 ± 0.007/μm2, respectively) or propofol (37.4
± 6.6 μm2, 0.041 ± 0.009/μm2, respectively) treated APP/
PS1 mice (p > 0.05, Fig. 1, Table 1). No Aβ plaques were
observed in the vehicle or propofol treated control mice.
Repeat propofol exposure did not alter plaque-associated
synaptic degeneration or the expression of synaptic
proteins in APP/PS1 mice
As propofol increases GABAergic activity and decreases
neuronal intrinsic excitability we assessed whether re-
peat propofol exposure altered the levels of excitatory
and inhibitory synaptic markers in control and APP/PS1
mice as well as plaque-associated synaptic degener-
ation in APP/PS1 mice. Western blot analysis showed
no robust difference in the expression levels of post-
synaptic density protein 95 (PSD-95), synaptophysin
and glutamic acid decarboxylase 65/67 (GAD65/67) in
the cortex between vehicle and propofol treated control or
APP/PS1 mice (Fig. 2). There was no difference in the
density of, or percentage area occupied by, synaptophysin-
immunoreactive synaptic puncta in the cortex < 40 μm
(region 1) from thioflavin-S plaques in vehicle (0.359 ± 0.
017/μm2, 1.55 ± 0.12%, respectively) or propofol (0.366 ±
0.03/μm2, 1.63 ± 0.17%, respectively) treated APP/PS1
mice (p > 0.05; Table 1). There was also no difference in
the density of, or percentage area occupied by
a b
c d e
Fig. 1 No difference in Aβ plaque load between propofol (n = 8) and vehicle (n = 6) treated APP/PS1 mice. a An example image of Aβ plaque
immunoreactivity in the cortex of an APP/PS1 mouse following repeated propofol exposure. b A representative image of Aβ plaque
immunolabeling the cortex of an APP/PS1 mouse following treatment with vehicle. c Bar graph showing the percentage of the cortex occupied
by Aβ plaques in propofol and vehicle treated APP/PS1 mice. d Bar graph showing the average size (μm2) of Aβ plaques in the cortex of APP/
PS1 in the propofol and vehicle treatment groups. e Bar graph showing the average density of Aβ plaques (/μm2) in the cortex of propofol and
vehicle exposed APP/PS1 mice. All data is shown as mean ± SEM. Scale bar = 500 μm
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synaptophysin-immunoreactive synaptic puncta in the cor-
tex between 40 and 80 μm (region 2) away from thioflavin-
S plaques in vehicle (0.268 ± 0.060/μm2, 2.57 ± 0.63%,
respectively) or propofol (0.234 ± 0.085/μm2, 2.37 ± 0.90%,
respectively) treated APP/PS1 mice (p > 0.05; Table 1).
Discussion
APP/PS1 and control mice were exposed to an average
of 54 min of propofol anesthesia repeatedly at 6, 7 and
8 months of age to determine the effect of repeat propo-
fol anesthesia on Aβ plaque pathology and synapses. We
detected no difference in plaque load, plaque-associated
synapse loss or the expression of excitatory and
inhibitory synaptic markers in APP/PS1 mice repeatedly
anesthetized with propofol compared to APP/PS1 ve-
hicle controls. We also provide some of the first evi-
dence suggesting that repeat propofol exposure in adult
wild-type mice does not result in robust long-term alter-
ations in the levels of PSD-95, synaptophysin and
GAD65/67.
Repeat propofol exposure did not result in a difference
in Aβ plaque load, plaque size or plaque density in APP/
PS1 mice in the current study. These data are in contrast
to the decreased Aβ load reported in 15-monthold
Tg2576 AD mice and Aβ levels in 18-month-old wild-
type mice following repeated propofol exposure [11, 37].
Differences in the AD mouse model used (Tg2576)
[11], the age of the animals, the dose of propofol
used (26 mg/kg bolus and 2 mg/kg/min infusion [11]
50 mg/kg bolus [37]), as well as the propofol dosing
regime [11, 37] may account for the differing impact
on Aβ dynamics reported between this and previous
studies. Our study focused on the impact of repeat
propofol anesthesia between 6 and 9 months of age
as Aβ plaque deposition occurs at a rapid rate in
APP/PS1 mice during this time [60]. It is possible
that the impact of propofol exposure in older APP/
PS1 mice may differ. Indeed, Shao and colleagues
(2014) observed improved performance in the Morris
Water Maze in 22-month-old APP/PS1 and aged
wild-type mice following weekly propofol exposure for
3 months [13]. In keeping with our data, behavioral
studies have observed that repeated propofol exposure
resulted in no difference in Y maze performance in
Table 1 Mean values with standard error (SEM) for Aβ plaque
deposition and synaptophysin immunoreactivity data
APP/PS1 APP/PS1
Propofol Vehicle
Aβ plaque load 3.85 ± 1.0% 3.80 ± 0.8%
Aβ plaque size 37.4 ± 6.6 μm2 41.6 ± 6.5 μm2
Aβ plaque density 0.041 ± 0.009/μm2 0.030 ± 0.007/μm2
Synapse density R1 0.366 ± 0.03/μm2 0.359 ± 0.017/μm2
Synapse % area R1 1.63 ± 0.17% 1.55 ± 0.12%,
Synapse density R2 0.234 ± 0.085/μm2 0.268 ± 0.060/μm2
Synapse % area R2 2.37 ± 0.90% 2.57 ± 0.63%
Aβ plaque load and Aβ plaque density were determined using the MOAβ-2
antibody in propofol (n = 8) and vehicle (n = 6) treated APP/PS1 mice
Synapse density and percentage area were analyzed in vehicle (n = 3) and
propofol (n = 3) treated APP/PS1 mice in: Region 1 (R1), < 40 μm from




Fig. 2 No change in synaptic proteins between propofol and vehicle treated APP/PS1 (n = 3 and 2) and control wild-type (n = 3 for both) mice.
Western blot analysis (a) showed no robust change in the expression levels of PSD-95, GAD65/67 and synaptophysin (SYN) in wild-type or APP/
PS1 mice treated multiple times with propofol (Prop) or vehicle (VH). Bar graphs show the mean intensity ± SEM of PSD-95 (b), GAD65/67 (c) and
synaptophysin (d) normalized to GAPDH
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Tg2576 AD mice [11]. Similarly, rat studies have reported
that one propofol exposure did not significantly alter ol-
factory learning in aged rats [61], while repeat propofol
exposure improved inhibitory avoidance performance
[62]. Interestingly, a recent human prospective study did
not detect a difference in cerebrospinal fluid levels of
Aβ1–42, total tau or phosphorylated tau between propofol
exposed and control MCI groups [9]. Furthermore, at 2
year follow-up no difference in the rate of MCI progres-
sion or conversion to AD between propofol exposed
(spinal surgery) MCI cases compared to non-surgery MCI
controls was detected [9].
Notably, as APP/PS1 mice do not exhibit substantial
tau pathology, it is possible that propofol may still influ-
ence the onset and/or progression of AD tau pathology.
However, a recent study investigated the impact of ~
30 min of propofol exposure in 3xTgAD mice, which de-
velop both Aβ and tau pathology indicates that this is
not the case [38]. Mardini and colleagues detected no
difference in performance between propofol exposed
and control 3xTgAD mice in the Morris Water Maze
both 3 weeks and 16 weeks following propofol exposure
[38]. Likewise, at 18 weeks following propofol exposure
there was no change in Aβ plaque load, phosphorylated-
tau aggregation or the number of activated microglia be-
tween the propofol exposed and control 3xTgAD mice
[38]. This suggests that transient increases in tau hyper-
phosphorylation in wild-type and transgenic AD mice
following a single propofol exposure [63, 64] does not
result in long-lasting sequelae.
As propofol is a GABAA agonist we investigated the
impact of repeat propofol anesthesia on the synaptic de-
generation and dysfunction that occurs in AD [47–49].
There was no exacerbation of the plaque-associated syn-
aptic loss in APP/PS1 mice treated with propofol versus
vehicle, suggesting that repeat propofol exposure
does not exacerbate synaptic degeneration. Furthermore,
we provide some of the first data that indicates that re-
peat propofol anesthesia in adult mice does not have a
robust long term effect on the levels of key excitatory
and inhibitory synaptic proteins; PSD-95, synaptophysin
and GAD65/67 were not altered between propofol and
vehicle treated cohorts of APP/PS1 or control mice. This
is pertinent as recent animal studies have suggested that
the dysfunction of inhibitory neuron networks contribute
to aberrant excitatory neuronal activity in AD [48, 49],
and decreased levels of GABAA receptor subunits have
been also observed in human AD [65–69]. These data in
adult mice are also in contrast to the long-lasting reduc-
tion in spine density in the prefrontal cortex observed fol-
lowing propofol exposure at P5 [45], as well as the
propofol-induced increase in dendritic spine density
in pyramidal neurons in the hippocampus and som-
atosensory cortex observed at P15 [46]. However, it
should be noted that the design of these developmen-
tal studies [45, 46] differed from the current study in
several ways including; the propofol dosing regime
(40-50 mg/kg propofol initial bolus with 1–1.5 hourly
injections of 20-25 mg/kg for a single 5–6 h propofol
exposure), analysis of synapses (spine density analysis
versus synaptic puncta analysis) and the brain region
analyzed (prefrontal cortex, somatosensory cortex and
hippocampus versus cingulate, motor and somatosen-
sory cortex); which may account for differences in the
synaptic data.
Conclusions
Our data, along with other studies investigating propofol
exposure and AD, suggest that propofol is unlikely to ex-
acerbate plaque deposition or synapse alterations in AD.
However, as the APP/PS1 mouse model does not de-
velop extensive tau pathology, it is important to note
that propofol may still impact neural health and could
mitigate the onset or progression of AD. This study also
provides some of the first data to demonstrate that key
synaptic markers are not altered in adult wild-type mice
following repeat propofol exposure.
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